Summary:
- This article discusses the results of a clinical trial that evaluated the effectiveness of the drug Xtandi (enzalutamide) in combination with the drug Leuprolide for the treatment of prostate cancer.
- The study found that the combination of Xtandi and Leuprolide reduced the risk of death by 40% compared to Leuprolide alone in men with prostate cancer.
- These findings suggest that the combination of Xtandi and Leuprolide may be a more effective treatment option for men with prostate cancer, potentially improving their overall survival.